523 related articles for article (PubMed ID: 33069769)
1. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai X; Ni J; Beretov J; Graham P; Li Y
Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
[TBL] [Abstract][Full Text] [Related]
2. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
5. Subtyping of triple-negative breast cancer: implications for therapy.
Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
8. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
10. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
11. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
[TBL] [Abstract][Full Text] [Related]
12. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
13. Recent therapeutic trends and promising targets in triple negative breast cancer.
Hwang SY; Park S; Kwon Y
Pharmacol Ther; 2019 Jul; 199():30-57. PubMed ID: 30825473
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
17. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA
Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525
[TBL] [Abstract][Full Text] [Related]
18. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
[TBL] [Abstract][Full Text] [Related]
20. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]